Antifungal Liposomes Targeted to Cell Wall Mannans

针对细胞壁甘露聚糖的抗真菌脂质体

基本信息

  • 批准号:
    9979038
  • 负责人:
  • 金额:
    $ 22.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-02-20 至 2022-01-31
  • 项目状态:
    已结题

项目摘要

Invasive fungal diseases (IFDs) cause millions of deaths each year and they are refractory to treatment. For instance, Candida albicans and Cryptococcus neoformans cause life-threatening invasive candidiasis and cryptococcosis, respectively. Patients at the greatest risk of developing these IFDs have weakened immune systems such as HIV positive individuals. The vulnerable population is increasing due to increasing numbers of immunosuppressed individuals receiving stem cell or organ transplants. Patients with candidiasis or cryptococcosis are treated with various antifungal drugs, but all antifungals have serious limitations due to human cell and organ toxicity, the emergence of resistant fungi, and the lack of sufficient fungicidal effect at safe doses. Even with the current antifungal therapies, these two IFDs are associated with dramatically increased medical costs, increased length of hospital stay, and one-year survival is only 12 to 90%, depending upon the patient population. Our proposal meets the critical need for improved antifungal therapeutics. A thick outer cell wall and secreted extracellular matrix rich in mannans, galactomannans, and mannoproteins help some pathogenic fungi including C. albicans and C. neoformans evade host defense. The C-type lectin receptor Dectin-2 on the surface of mammalian lymphocytes bind strongly to mannans in the fungal cell wall, matrix, and solubilized into tissue to signal an innate immune response to infection. We have strong preliminary data showing that truncated Dectin-2 functions in a liposomal membrane. Dectin-2-coated antifungal drug-loaded liposomes bind mannans in the cell-associated exopolysaccharide matrix of C. albicans and C. neoformans two orders of magnitude more efficiently than uncoated liposomes and kills both species an order of magnitude more efficiently. The overarching goal of this exploratory proposal is to demonstrate Dectin- 2-targeted antifungal loaded liposomes increase antifungal drug efficacy as compared to current antifungal drugs. In particular, we will show that Dectin-2-coated drug-loaded liposomes have enhanced antifungal activity toward C. albicans and C. neoformans in vitro and efficiently treat disseminated candidiasis in an in vivo mouse model. We have an established team of scientists already combining their expertise in diverse areas of science necessary to carry out these experiments including fungal biology and pathology, immunology and liposome biochemistry, genetics, and protein chemistry. Successful completion of this study will establish the feasibility of antifungal drug delivery specifically to fungal mannans that will ultimately improve outcomes of patients with candidiasis, aspergillosis, and cryptococcosis. We will have developed an experimental platform to rapidly innovate and optimize fungal mannan and biofilm targeted therapies that may be used to treat diverse life- threatening fungal infections and milder fungal infections of eyes, skin, toenails, and biomedical devices.
侵袭性真菌病(IFD)每年导致数百万人死亡,并且难以治疗。 例如,白色念珠菌和新型隐球菌引起危及生命的侵袭性念珠菌病, 隐球菌病。发生这些IFD风险最大的患者的免疫力较弱, 艾滋病病毒感染者等。由于越来越多的人, 接受干细胞或器官移植的免疫抑制个体。念珠菌病患者或 隐球菌病可以用各种抗真菌药物治疗,但所有的抗真菌药物都有严重的局限性, 人体细胞和器官毒性,耐药真菌的出现,以及缺乏足够的杀真菌效果, 安全剂量即使使用目前的抗真菌治疗,这两种IFD也与显著的 医疗费用增加,住院时间延长,一年生存率仅为12%至90%,具体取决于 患者人群。我们的建议满足了改善抗真菌治疗的迫切需要。 厚的外细胞壁和分泌的细胞外基质,富含甘露聚糖、半乳甘露聚糖和 甘露糖蛋白有助于某些病原真菌,包括C.白色念珠菌和念珠菌。新型生物逃避宿主的防御的 哺乳动物淋巴细胞表面的C-型凝集素受体Dectin-2与甘露聚糖强烈结合, 真菌细胞壁、基质,并溶解到组织中以发出对感染的先天免疫应答的信号。我们有 强有力的初步数据显示截短的Dectin-2在脂质体膜中起作用。Dectin-2涂层 抗真菌药物负载的脂质体结合C.白色 和C.比未涂覆的脂质体更有效地杀死两个数量级的新形式, 数量级更高效。这个探索性提案的首要目标是展示Dectin- 2-与目前的抗真菌药物相比,靶向的抗真菌负载脂质体增加了抗真菌药物的功效 毒品特别是,我们将证明Dectin-2包被的载药脂质体具有增强的抗真菌作用。 活性向C.白色念珠菌和C.在体外培养新型念珠菌,并在体内有效治疗播散性念珠菌病 小鼠体内模型。 我们有一个成熟的科学家团队,他们已经结合了不同科学领域的专业知识 这些实验包括真菌生物学和病理学、免疫学和脂质体 生物化学、遗传学和蛋白质化学。本研究的成功完成将确立 的抗真菌药物输送,特别是真菌甘露聚糖,最终将改善患者的结果, 念珠菌病、曲霉病和隐球菌病。我们将开发一个实验平台, 创新和优化真菌甘露聚糖和生物膜靶向疗法,可用于治疗各种生命- 威胁性真菌感染和眼睛、皮肤、脚趾甲和生物医学设备的轻度真菌感染。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard Brian Meagher其他文献

Richard Brian Meagher的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard Brian Meagher', 18)}}的其他基金

Targeted pan-antibacterial liposomes to control pathogenic mycobacteria
靶向泛抗菌脂质体控制致病性分枝杆菌
  • 批准号:
    10569282
  • 财政年份:
    2023
  • 资助金额:
    $ 22.65万
  • 项目类别:
Targeted delivery of antifungal drug loaded liposomes to control mucormycosis
靶向递送抗真菌药物脂质体来控制毛霉菌病
  • 批准号:
    10668509
  • 财政年份:
    2022
  • 资助金额:
    $ 22.65万
  • 项目类别:
Targeted delivery of antifungal drug loaded liposomes to control mucormycosis
靶向递送抗真菌药物脂质体来控制毛霉菌病
  • 批准号:
    10509943
  • 财政年份:
    2022
  • 资助金额:
    $ 22.65万
  • 项目类别:
Antifungal Imunoliposomes
抗真菌免疫脂质体
  • 批准号:
    9926213
  • 财政年份:
    2019
  • 资助金额:
    $ 22.65万
  • 项目类别:
NUCLEAR CAPTURE FOR CELL-TYPE SPECIFIC EPIGENETIC ANALYSIS OF ADIPOCYTES
用于脂肪细胞细胞类型特异性表观遗传分析的核捕获
  • 批准号:
    8760476
  • 财政年份:
    2014
  • 资助金额:
    $ 22.65万
  • 项目类别:
NUCLEAR CAPTURE FOR CELL-TYPE SPECIFIC EPIGENETIC ANALYSIS OF ADIPOCYTES
用于脂肪细胞细胞类型特异性表观遗传分析的核捕获
  • 批准号:
    8917210
  • 财政年份:
    2014
  • 资助金额:
    $ 22.65万
  • 项目类别:
Differential Expression of the Diverse Plant Actins
多种植物肌动蛋白的差异表达
  • 批准号:
    7931495
  • 财政年份:
    2009
  • 资助金额:
    $ 22.65万
  • 项目类别:
PLANT MOLECULAR BIOLOGY GORDON CONFERENCE
植物分子生物学戈登会议
  • 批准号:
    3435014
  • 财政年份:
    1988
  • 资助金额:
    $ 22.65万
  • 项目类别:
DIFFERENTIAL EXPRESSION OF DIVERSE PLANT ACTIN GENES
多种植物肌动蛋白基因的差异表达
  • 批准号:
    6039284
  • 财政年份:
    1986
  • 资助金额:
    $ 22.65万
  • 项目类别:
DIFFERENTIAL EXPRESSION OF DIVERSE PLANT ACTIN GENES
多种植物肌动蛋白基因的差异表达
  • 批准号:
    2684820
  • 财政年份:
    1986
  • 资助金额:
    $ 22.65万
  • 项目类别:

相似海外基金

有機分子触媒を用いたAmphotericin Bの合成研究
有机分子催化剂合成两性霉素B的研究
  • 批准号:
    24K17671
  • 财政年份:
    2024
  • 资助金额:
    $ 22.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
EnLAmB - Enabling global access to affordable generic liposomal amphotericin B injectable formulations via advanced manufacturing technology
EnLAmB - 通过先进的制造技术,使全球能够获得负担得起的通用脂质体两性霉素 B 注射制剂
  • 批准号:
    MR/X014010/1
  • 财政年份:
    2023
  • 资助金额:
    $ 22.65万
  • 项目类别:
    Research Grant
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
  • 批准号:
    559052-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 22.65万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Study on naturally-occurring peptides potentiating amphotericin B activity
天然存在的肽增强两性霉素 B 活性的研究
  • 批准号:
    22K05333
  • 财政年份:
    2022
  • 资助金额:
    $ 22.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
  • 批准号:
    559052-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 22.65万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
  • 批准号:
    10024667
  • 财政年份:
    2020
  • 资助金额:
    $ 22.65万
  • 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
  • 批准号:
    9909193
  • 财政年份:
    2020
  • 资助金额:
    $ 22.65万
  • 项目类别:
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
  • 批准号:
    10248529
  • 财政年份:
    2020
  • 资助金额:
    $ 22.65万
  • 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
  • 批准号:
    10484014
  • 财政年份:
    2020
  • 资助金额:
    $ 22.65万
  • 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
  • 批准号:
    10654834
  • 财政年份:
    2020
  • 资助金额:
    $ 22.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了